Validation Doppler Flow used worldwide to measure coronary blood flow.
First case in U.S. to measure coronary artery pressure and fractional flow reserve, conducted at Harvard University.
Joins the Arizona Heart Institute as Director of Interventional Cardiovascular Research.
First worldwide experiment to demonstrate the feasibility of stem cell transplantation using 3-D catheter guidance.
Implanted the first patient with stem cell therapy using surgical approach.
Stem Cell Therapy “Best of the Session” presented at the American Heart Association in Chicago, Ill.
Presented the first abstract demonstrating that stem cell transplantation can replace scar tissue with cardiac-like muscle.
Dr. Dib announces new procedure for repairing hearts damaged in heart attack.
Obtains the first FDA approval in the United States for stem cell transplantation to patients with heart failure and heart attack using the 3-D catheter guidance technology.
Authors a book titled: Stem cell therapy and tissue engineering for cardiovascular repair
Founded Cardiovascular and Stem Cell Consultants (CSCC) in Gilbert, Ariz.
Founded the Journal of Cardiovascular Translational Research (JCTR), where he serves as Editor in Chief.
Founded the International Society for CardioVascular Translational Research (ISCTR), where he serves as President.
Completes Phase I of a clinical trial that uses a three-dimensional guided catheter system to deliver muscular stem cells to the heart and showed that one can reverse the progression of heart failure. Clinical trial results presented in American College of Cardiology.
Appointed Associate Professor of Medicine and Director of Clinical Cardiovascular Stem Cell Therapy at University of California San Diego (UCSD).
Appointed Director of Cardiovascular Research and New Devices at Mercy Gilbert & Chandler Regional Medical centers, a Catholic Healthcare West facility.
UCSD tests adult stem cells to repair hearts
First world stem cell transplantation using 3-D catheter guidance technology to patient suffering from congestive heart failure, including those with non-ischemic cardiomyopathy, using stem cells from an unrelated, universal donor
Appointed International Principal Investigator for clinical trial in patients with severe coronary heart disease.
The First US Study to Assess the Feasibility and Safety of Endocardial Delivery of Allogenic Mesenchymal Precursor Cells in Patient With Heart Failure: Three-Month Interim Analysis
We are a full-service cardiology practice led by world-renowned cardiovascular doctor and researcher, Nabil Dib, M.D., MSc, FACC.